Literature DB >> 29891204

Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site.

Heather M McGee1, Megan E Daly2, Sohelia Azghadi3, Susan L Stewart4, Leslie Oesterich5, Jeffrey Schlom6, Renee Donahue6, Jonathan D Schoenfeld7, Qian Chen8, Shyam Rao3, Ruben C Fragoso3, Richard K Valicenti3, Robert J Canter8, Emmanual M Maverakis8, William J Murphy9, Karen Kelly5, Arta M Monjazeb10.   

Abstract

PURPOSE: Despite the strong interest in combining stereotactic ablative radiation therapy (SAR) with immunotherapy, limited data characterizing the systemic immune response after SAR are available. We hypothesized that the systemic immune response to SAR would differ by irradiated site owing to inherent differences in the microenvironment of various organs. METHODS AND MATERIALS: Patients receiving SAR to any organ underwent prospective blood banking before and 1 to 2 weeks after SAR. Peripheral blood mononuclear cells (PBMCs) and serum were isolated. PBMCs were stained with fluorophore-conjugated antibodies against T and natural killer (NK) cell markers. Cells were interrogated by flow cytometry, and the results were analyzed using FlowJo software. Serum cytokine and chemokine levels were measured using Luminex. We analyzed the changes from before to after therapy using paired t tests or 1-way analysis of variance (ANOVA) with Bonferroni's post-test.
RESULTS: A total of 31 patients had evaluable PBMCs for flow cytometry and 37 had evaluable serum samples for Luminex analysis. The total number of NK cells and cytotoxic (CD56dimCD16+) NK cells decreased (P = .02) and T-cell immunoglobulin- and mucin domain-containing molecule-3-positive (TIM3+) NK cells increased (P = .04) after SAR to parenchymal sites (lung and liver) but not to bone or brain. The total memory CD4+ T cells, activated inducible co-stimulator-positive and CD25+CD4+ memory T cells, and activated CD25+CD8+ memory T cells increased after SAR to parenchymal sites but not bone or brain. The circulating levels of tumor necrosis factor-α (P = .04) and multiple chemokines, including RANTES (P = .04), decreased after SAR to parenchymal sites but not bone or brain.
CONCLUSIONS: Our data suggest SAR to parenchymal sites induces systemic immune changes, including a decrease in total and cytotoxic NK cells, an increase in TIM3+ NK cells, and an increase in activated memory CD4+ and CD8+ T cells. SAR to nonparenchymal sites did not induce these changes. By comparing the immune response after radiation to different organs, our data suggest SAR induces systemic immunologic changes that are dependent on the irradiated site.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29891204      PMCID: PMC6364565          DOI: 10.1016/j.ijrobp.2018.04.038

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  65 in total

Review 1.  A practical approach to multicolor flow cytometry for immunophenotyping.

Authors:  N Baumgarth; M Roederer
Journal:  J Immunol Methods       Date:  2000-09-21       Impact factor: 2.303

2.  An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.

Authors:  Encouse B Golden; Sandra Demaria; Peter B Schiff; Abraham Chachoua; Silvia C Formenti
Journal:  Cancer Immunol Res       Date:  2013-12       Impact factor: 11.151

3.  Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.

Authors:  Ines Pires da Silva; Anne Gallois; Sonia Jimenez-Baranda; Shaukat Khan; Ana C Anderson; Vijay K Kuchroo; Iman Osman; Nina Bhardwaj
Journal:  Cancer Immunol Res       Date:  2014-02-11       Impact factor: 11.151

4.  Mesenchymal and haematopoietic stem cells form a unique bone marrow niche.

Authors:  Simón Méndez-Ferrer; Tatyana V Michurina; Francesca Ferraro; Amin R Mazloom; Ben D Macarthur; Sergio A Lira; David T Scadden; Avi Ma'ayan; Grigori N Enikolopov; Paul S Frenette
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

5.  Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy.

Authors:  Derek Ng Tang; Yu Shen; Jingjing Sun; Sijin Wen; Jedd D Wolchok; Jianda Yuan; James P Allison; Padmanee Sharma
Journal:  Cancer Immunol Res       Date:  2013-07-31       Impact factor: 11.151

6.  Local Microenvironment Controls the Compartmentalization of NK Cell Responses during Systemic Inflammation in Mice.

Authors:  Orhan Rasid; Ioana Sonya Ciulean; Catherine Fitting; Noelle Doyen; Jean-Marc Cavaillon
Journal:  J Immunol       Date:  2016-08-12       Impact factor: 5.422

7.  Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody.

Authors:  M Zahidunnabi Dewan; Ashley E Galloway; Noriko Kawashima; J Keith Dewyngaert; James S Babb; Silvia C Formenti; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

Review 8.  Systemic effects of local radiotherapy.

Authors:  Silvia C Formenti; Sandra Demaria
Journal:  Lancet Oncol       Date:  2009-07       Impact factor: 41.316

9.  Cryopreservation decreases receptor PD-1 and ligand PD-L1 coinhibitory expression on peripheral blood mononuclear cell-derived T cells and monocytes.

Authors:  D E Campbell; N B Tustin; E Riedel; R Tustin; J Taylor; J Murray; S D Douglas
Journal:  Clin Vaccine Immunol       Date:  2009-09-02

10.  A role for the chemokine RANTES in regulating CD8 T cell responses during chronic viral infection.

Authors:  Alison Crawford; Jill Marie Angelosanto; Kim Lynn Nadwodny; Shawn D Blackburn; E John Wherry
Journal:  PLoS Pathog       Date:  2011-07-21       Impact factor: 6.823

View more
  15 in total

Review 1.  Effects of Radiation on the Tumor Microenvironment.

Authors:  Arta M Monjazeb; Kurt A Schalper; Franz Villarroel-Espindola; Anthony Nguyen; Stephen L Shiao; Kristina Young
Journal:  Semin Radiat Oncol       Date:  2020-04       Impact factor: 5.934

Review 2.  Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?

Authors:  Jonathan Khalifa; Julien Mazieres; Carlos Gomez-Roca; Maha Ayyoub; Elizabeth Cohen-Jonathan Moyal
Journal:  Front Oncol       Date:  2021-04-21       Impact factor: 6.244

3.  Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy.

Authors:  Jeongshim Lee; Jee Suk Chang; Mi Ryung Roh; Minkyu Jung; Choong-Kun Lee; Byung Ho Oh; Kee Yang Chung; Woong Sub Koom; Sang Joon Shin
Journal:  Cancer Res Treat       Date:  2020-02-13       Impact factor: 4.679

Review 4.  Immunomodulation of NK Cells by Ionizing Radiation.

Authors:  Jiarui Chen; Xingyu Liu; Zihang Zeng; Jiali Li; Yuan Luo; Wenjie Sun; Yan Gong; Junhong Zhang; Qiuji Wu; Conghua Xie
Journal:  Front Oncol       Date:  2020-06-16       Impact factor: 6.244

5.  Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma.

Authors:  Philippe Rochigneux; Jean-Charles Nault; Françoise Mallet; Anne-Sophie Chretien; Nathalie Barget; Alejandro J Garcia; Lucie Del Pozo; Valérie Bourcier; Lorraine Blaise; Véronique Grando-Lemaire; Gisèle N'Kontchou; Pierre Nahon; Olivier Seror; Marianne Ziol; Nathalie Ganne-Carrié; Daniel Olive
Journal:  Oncoimmunology       Date:  2019-05-25       Impact factor: 8.110

Review 6.  Integration of immuno-oncology with stereotactic radiosurgery in the management of brain metastases.

Authors:  Eric J Lehrer; Heather M McGee; Jason P Sheehan; Daniel M Trifiletti
Journal:  J Neurooncol       Date:  2020-02-12       Impact factor: 4.130

7.  Changes in T Lymphocyte Subsets in Different Tumors Before and After Radiotherapy: A Meta-analysis.

Authors:  Qin Wang; Shangbiao Li; Simiao Qiao; Zhihao Zheng; Xiaotong Duan; Xiaoxia Zhu
Journal:  Front Immunol       Date:  2021-06-16       Impact factor: 7.561

8.  A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.

Authors:  Umair Mahmood; Andrew Bang; Yu-Hui Chen; Raymond H Mak; Jochen H Lorch; Glenn J Hanna; Mizuki Nishino; Claire Manuszak; Emily M Thrash; Mariano Severgnini; Matthew Sanborn; Vishwajith Sridharan; Danielle N Margalit; Roy B Tishler; Paul M Busse; Henning Willers; Harvey J Mamon; Hyung-Jin Yoo; Sara I Pai; Lori J Wirth; Robert I Haddad; Nicole G Chau; Jonathan D Schoenfeld
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-08-08       Impact factor: 8.013

Review 9.  A Clinician's Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications.

Authors:  Matthew C Knox; Jie Ni; Andrej Bece; Joseph Bucci; Yaw Chin; Peter H Graham; Yong Li
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

Review 10.  Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases.

Authors:  Eric J Lehrer; Heather M McGee; Jennifer L Peterson; Laura Vallow; Henry Ruiz-Garcia; Nicholas G Zaorsky; Sonam Sharma; Daniel M Trifiletti
Journal:  Int J Mol Sci       Date:  2018-10-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.